IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q4 2025 Holdings

Filed 2026-02-10 | 13 holdings | $478.9M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
BridgeBio Pharma Inc. (Bbio)(BBIO)COM10806X102$389.3M5,089,61181.3%
Syndax Pharmaceuticals, Inc. (Sndx)(SNDX)COM87164F105$27.7M1,316,8065.8%
Monte Rosa Therapeutics Inc (Glue)(GLUE)COM61225M102$23.1M1,472,3314.8%
Bicara Therapeutics Inc. (Bcax)(BCAX)COM055477103$9.6M568,9192.0%
Compass Pathways Plc (Cmps)(CMPS)SPONSORED ADS20451W101$8.3M1,198,4181.7%
BridgeBio Oncology Therapeutics (Bbot)(BBOT)COM NEW107924102$7.1M564,6251.5%
CalciMedica, Inc. (Calc)(CALC)COM NEW38942Q202$3.4M521,1140.7%
Scholar Rock Holding Corporation (Srrk)(SRRK)COM80706P103$3.4M77,0310.7%
Biomea Fusion Inc (Bmea)(BMEA)COM09077A106$2.5M2,048,7570.5%
Urogen Pharma Ltd. (Urgn)(URGN)COMM96088105$2.5M108,0000.5%
Aclaris Therapeutics Inc (Acrs)(ACRS)COM00461U105$1.3M434,4550.3%
Marker Therapeutics, Inc. (Mrkr)(MRKR)COM NEW57055L206$484.8K325,3700.1%
OnKure Therapeutics, Inc. (Okur)(OKUR)COM CL A68277Q105$257.0K88,6070.1%